Moderna : Tricky comparison base for future entrants
>Room for everyone, but mRNA shows superior efficiency - Friday was full of news about the COVID-19 vaccine. We had the clinical results of two phase III trials, Novavax and JnJ, as well as the approval of the third COVID-19 vaccine in Europe from AstraZeneca.While we might have initially thought that this news could have impacted early entrants, we believe that it has reinforced our call on mRNA technology. Recap of the context: Novavax (recombinant protein...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.